SC
TARS icon

Stephens Consulting’s Tarsus Pharmaceuticals TARS Stock Holding History

Stephens Consulting’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$514 – 1920
2025
Q1 		$514 Buy
+10
New +$494 ﹤0.01% 913

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Stephens Consulting's TARS Position: Q2 2025 in Review

Stephens Consulting sold out of Tarsus Pharmaceuticals (TARS) in Q2 2025, closing a stake of 10 shares — an estimated $514 sold.

Stephens Consulting first reported a position in TARS in Q1 2025 and held it in 1 quarter. The position peaked at $514 in Q1 2025. 205 funds tracked by Wall St. Rank hold TARS as of Q2 2025.

  • Stephens Consulting reported no remaining Tarsus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 10 Tarsus Pharmaceuticals shares in Q2 2025, an estimated $514.
  • Stephens Consulting first reported a position in Tarsus Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Tarsus Pharmaceuticals position peaked at $514 in Q1 2025.
  • 205 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.